Teclistamab plus daratumumab significantly boosts survival for patients with early RRMM

This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, according to results of the phase 3 MajesTEC‐3 trial, the combination of teclistamab plus daratumumab in patients with early relapsed myeloma significantly improved progression‐free survival and led to an overall survival advantage in comparison with the standard of care in patients with relapsed or refractory multiple myeloma. In addition, ASTRO recently published its